Antiviral Drugs: The Unmet Requirement in the Pharmaceutical Space

Over the past few years, a number of antiviral drugs targeting a myriad of infectious diseases, including human immunodeficiency virus (HIV) infection, hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19) and others, have received approvals from various regulatory authorities, globally. However, it is important to note that, currently, the approved antiviral drugs (around 80) are capable of targeting only 10 of the 220 known viruses that are responsible for causing multiple life threatening infectious diseases in humans.

Further, several these drugs are being evaluated across multiple clinical trials for the treatment of various infectious diseases. Moreover, post the onset of the COVID-19 pandemic, extensive research is being conducted to evaluate the safety and efficacy of novel antiviral therapeutics. Presently, more than 375 companies are engaged in the development of over 420 early and late-stage antiviral drugs, worldwide. These stakeholders have established multiple partnerships and collaborations in order to advance the development of various pipeline candidates.

Most of these drugs are designed to inhibit viral fusion with the host cell, prevent virus replication and protein synthesis, thus inhibiting the reproduction and spread of virus to healthy cells. Some of the mechanism of actions of these drugs are outlined below:

Approved Antiviral Drugs: Current Market Landscape

Close to 80 anti-viral drugs have been approved, till date, for the treatment of an array of infectious diseases; nearly 75% of these drugs are administered via oral route. Further, more than 45% of the anti-viral drugs were approved post 2010; majority (~90%) of the approved drugs are small molecules, available in tablet and liquid formulations. It is worth highlighting that of the total approved antiivral drugs, over 40 drugs have been approved to treat HIV infection, and  polymerase inhibition is the most common mechanism of action exhibited by majority of the approved antiviral drugs.

Billions of Dollars are Being Invested in Funding the Initiatives of Various Players Engaged in the Antiviral Drugs Domain

Maximum number of funding instances (49) were reported in the year 2020, followed by 44 instances, recorded in the year 2021. Further, Most of the funding instances reported by antiviral drug developers were venture capital rounds (30). Given the current trend, it can be inferred that investment from venture funding rounds is a key enabler for the growth in this domain.

Future Evolution of Antiviral Drugs Market

During our research, we estimated the market under conservative, base and optimistic scenarios. As per the base case forecast scenario, the market for antiviral drugs is estimated to grow at an annualized rate of 6.3%, in the given time period. The opportunity associated with the antiviral drugs market is likely to be well distributed across various types of drug targets, therapies, and key geographical regions. You can also download the SAMPLE REPORT on this topic by Roots Analysis by clicking on the link here…https://www.rootsanalysis.com/reports/antiviral-drugs-market.html